good for some but not for all - werkgeversreview Senior Specialist bij Merck

1,0
28 jul 2014
Aanbevelen
Goedkeuring directeur
Zakelijk vooruitzicht

Pluspunten

Pay is pretty good relative to industry standards. There may be more opportunities for employment and promotion given the increase in attrition over the last 4 months.

Minpunten

hard work often goes unappreciated and overlooked when it comes to contributions. I you are used to a meritocracy where you get rewarded for your exceptional efforts, this company may not be the best fit for you. If you are the type of person that knows and plays the game of posturing and pontification, then you will do very well for yourself in the company. Inclusion efforts are always overshodowed by the underlying and overbearing need to accomplish results at any cost. Many people have been overworked and enundated with tasks beyond their job descriptions in the effort to do more with less. Merck is not in its "golden age" right now, but I believe that in the coming years they will cycle back around to being a company that people are excited to work for again. I hope Merck gets it back together soon, because damage to company reputation by the opinions of former employees, could take a much greater effort than maintaining a good relationship from the start.

Ontdek andere reviews over Merck

5,0
30 jun 2026
Aanbevelen
Goedkeuring directeur
Zakelijk vooruitzicht

Pluspunten

Excellent company to work with.

Minpunten

No cons encountered so far

4,0
30 jun 2026
Aanbevelen
Goedkeuring directeur
Zakelijk vooruitzicht

Pluspunten

Great benefits like medical/dentist/vision, pension, stock option, 401k match. Co workers are excellent, pretty good on site symposiums, lot of diversity clubs/activities. Innovation is extremely welcomed. Diversity in research portfolio. AI/ML is heavily invested to make databases more efficient.

Minpunten

Micro managing, especially within the biologics department, potentially others. Promotions are limited, and pay bump is poor. Company invests too much in buying companies rather than keeping talent - lay offs let go of great talented people. Merck is afraid of investing into exploratory biology and doesn’t take risk - they even admit they would rather see other companies clinical data or R&D data rather than taking a risk. Although it’s slow going in building new software, current databases are slow and needs much improvement. Extremely poor work/life balance.

Bekijk reviews op: Nuttig|Beoordeling|Datum|Alle